Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 12/20 | 0.79 |
| ▸ | AR | P10275 | 11/20 | 0.79 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.79 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.79 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.79 |
| ▸ | HTR2A | P28223 | 1/20 | 0.79 |
| ▸ | HTR2B | P41595 | 1/20 | 0.79 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14668731 | 1.00 | PGR (0.79) | PGRARNR3C1LMNACHRM2 | |
| SCHEMBL8025172 | 1.00 | PGR (0.79) | PGRARNR3C1LMNACHRM2 | |
| SCHEMBL14256379 | 1.00 | PGR (0.79) | PGRARNR3C1LMNACHRM2 | |
| SCHEMBL18220876 | 1.00 | PGR (0.79) | PGRARNR3C1LMNACHRM2 | |
| SCHEMBL22171518 | 0.90 | PGR (0.76) | PGRARNR3C1LMNACHRM2 | |
| SCHEMBL19067844 | 0.90 | PGR (0.76) | PGRARNR3C1LMNACHRM2 | |
| SCHEMBL22382732 | 0.90 | PGR (0.76) | PGRARNR3C1LMNACHRM2 | |
| SCHEMBL11029288 | 0.89 | PGR (0.71) | PGRARNR3C1LMNACHRM2 | |
| SCHEMBL11026949 | 0.89 | PGR (0.71) | PGRARNR3C1LMNACHRM2 | |
| SCHEMBL14267085 | 0.89 | PGR (0.62) | PGRARNR3C1LMNACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053947-A1 | Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053947-A1 | Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | PGC, LIPC, CEL | PGR 1141/4885AR 1971/4885NR3C1 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.